Condition: Diabetes Mellitus, Type 2 · Sponsor: Daewoong Pharmaceutical Co. LTD.
This observational study is a non-interventional, multi-center, prospective observational study aimed at tracking the efficacy and safety of Envlo or Envlomet SR tablets for 24 weeks in patients with type 2 diabetes and hypertension or dyslipidemia who are currently taking or are scheduled to take Envlo or Envlomet SR tablets in an actual clinical setting.
This description comes directly from the study's public registry record.
Ji Yeon Baeg · 82-02-550-8419 · bjy469@daewoong.co.kr
Always discuss trial participation with your own doctor first.
| Happy Yonsei Family Medicine Clinic | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06647888